Regeneron Pharmaceuticals (REGN) News Today $700.33 +4.31 (+0.62%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$703.93 +3.60 (+0.51%) As of 02/21/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period US must meet tougher standard in Regeneron kickback lawsuitFebruary 21 at 5:16 PM | reuters.comRegeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – REGNFebruary 21 at 1:44 PM | globenewswire.comRegeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens BermanFebruary 21 at 1:30 PM | globenewswire.comROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGNFebruary 21 at 1:13 PM | investing.comPharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & MoreFebruary 21 at 12:14 PM | msn.comRegeneron Pharmaceuticals Q4 Earnings TranscriptFebruary 21 at 7:11 AM | marketbeat.comHussman Strategic Advisors Inc. Purchases Shares of 2,100 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Hussman Strategic Advisors Inc. purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,100 shares of the biopharmaceuticalFebruary 21 at 6:44 AM | marketbeat.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGNFebruary 21 at 5:45 AM | prnewswire.comHandelsbanken Fonder AB Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Handelsbanken Fonder AB lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 42.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 48,154 shares of the biopharmaceutical cFebruary 21 at 4:54 AM | marketbeat.comREGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud LawsuitFebruary 21 at 12:39 AM | prnewswire.comROSEN, LEADING TRIAL ATTORNEYS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGNFebruary 20 at 7:26 PM | globenewswire.comRegeneron Pharmaceuticals Faces Legal and Financial Challenges Amidst Investor ConcernsFebruary 20 at 6:58 PM | gurufocus.comREGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitFebruary 20 at 4:00 PM | globenewswire.comShareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) should contact The Gross Law Firm about pending Class Action - REGNFebruary 20 at 1:27 PM | globenewswire.comRegeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitFebruary 20 at 12:00 PM | prnewswire.comFaruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGNFebruary 20 at 11:38 AM | prnewswire.comBiogen Stock Is Mutating Into a Value Play (REGN)Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2XFebruary 20 at 7:42 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Fagan Associates Inc.Fagan Associates Inc. grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 42.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,923 shares of the biopharmaceutical companFebruary 20 at 7:41 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGNFebruary 20 at 5:45 AM | prnewswire.comAlberta Investment Management Corp Invests $5.06 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Alberta Investment Management Corp bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 7,100 shares of the biopharmFebruary 20 at 4:54 AM | marketbeat.com842 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Kornitzer Capital Management Inc. KSKornitzer Capital Management Inc. KS bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 842February 20 at 4:19 AM | marketbeat.comRegeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens BermanFebruary 19 at 4:04 PM | globenewswire.comCallahan Advisors LLC Acquires Shares of 866 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Callahan Advisors LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 866 shares of the biopharmaceutical company'sFebruary 19 at 5:40 AM | marketbeat.comKestra Investment Management LLC Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Kestra Investment Management LLC increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 104.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,260 shares of the biopharmaceutical company's stock afterFebruary 19 at 5:15 AM | marketbeat.comTruist Financial Corp Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Truist Financial Corp increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 59.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 59,303 shares of the biopharmaceutical company's stock after buyFebruary 19 at 4:56 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Principal Financial Group Inc.Principal Financial Group Inc. lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 24.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 130,490 shares of the biophFebruary 19 at 4:39 AM | marketbeat.comRegeneron Pharmaceuticals Inc (REGN) Announces FDA Priority Review for Dupixent in Treating ...February 18, 2025 | gurufocus.comREGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025February 18, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGNFebruary 18, 2025 | prnewswire.comRegeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitFebruary 18, 2025 | prnewswire.comThis Company Just Initiated a Quarterly Dividend: Time to Buy?February 18, 2025 | fool.comBraun Stacey Associates Inc. Sells 654 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Braun Stacey Associates Inc. lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,492 shares of the biopharmaceutical company'February 18, 2025 | marketbeat.comCIBC Asset Management Inc Has $24.49 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)CIBC Asset Management Inc raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,386 shares of the biopharmaceutical company's stock after purchasiFebruary 18, 2025 | marketbeat.comEverhart Financial Group Inc. Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Everhart Financial Group Inc. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 59.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 352 shares of the biopharmaceutical company's stock aftFebruary 18, 2025 | marketbeat.comMontag A & Associates Inc. Sells 644 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Montag A & Associates Inc. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 82.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 139 shares of the biopharmaceutical company's stockFebruary 18, 2025 | marketbeat.comDupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)February 18, 2025 | globenewswire.comROSEN, A GLOBALLY RESPECTED LAW FIRM , Encourages Regeneron Pharmaceuticals, Inc. ...February 17, 2025 | gurufocus.comROSEN, A GLOBALLY RESPECTED LAW FIRM , Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGNFebruary 17, 2025 | globenewswire.comRegeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report– Hagens BermanFebruary 17, 2025 | globenewswire.comAlphaCentric Advisors LLC Invests $350,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)AlphaCentric Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 491 shares of the biopharmaceutical coFebruary 17, 2025 | marketbeat.comWhy Regeneron's Price May Soon Break OutFebruary 16, 2025 | seekingalpha.comEmpire Life Investments Inc. Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Empire Life Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 14.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 4,080 shares of the biopharmaceutical company's stock after selling 705 shares during the peFebruary 16, 2025 | marketbeat.comABC Arbitrage SA Acquires Shares of 2,120 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)ABC Arbitrage SA purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,120 shares of the biopharmaceFebruary 16, 2025 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Rhumbline AdvisersRhumbline Advisers cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 170,620 shares of the bFebruary 16, 2025 | marketbeat.comVontobel Holding Ltd. Buys 2,322 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Vontobel Holding Ltd. raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 56.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 6,458 shares of the biopharmaceutical company's stock after purchasing anFebruary 16, 2025 | marketbeat.comREGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud LawsuitFebruary 15, 2025 | prnewswire.comNew York State Teachers Retirement System Lowers Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)New York State Teachers Retirement System cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 97,811 sFebruary 15, 2025 | marketbeat.comKlingenstein Fields & Co. LP Buys 6,231 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Klingenstein Fields & Co. LP raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1,083.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,806 shares of the biopharmaceutical company's stock after buyingFebruary 15, 2025 | marketbeat.comChevy Chase Trust Holdings LLC Has $163.67 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Chevy Chase Trust Holdings LLC lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 229,767 shares of the biopharmaceutical cFebruary 15, 2025 | marketbeat.comBanque Pictet & Cie SA Acquires Shares of 6,312 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Banque Pictet & Cie SA acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 6,312 shares of the biopharmaceutical company's stock, valued at approximately $4,496,000February 15, 2025 | marketbeat.com Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Media Mentions By Week REGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REGN News Sentiment▼0.460.60▲Average Medical News Sentiment REGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REGN Articles This Week▼5323▲REGN Articles Average Week Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amgen News Gilead Sciences News Vertex Pharmaceuticals News Alnylam Pharmaceuticals News Biogen News United Therapeutics News Incyte News BioMarin Pharmaceutical News Neurocrine Biosciences News Exelixis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REGN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
